Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study
12 Health Care Stocks Moving In Friday's Intraday Session
RFK Jr. to Reinstate 20% of HHS Staff Laid off After DOGE Errors
Amgen, Sabra Health Care And A Financial Stock On CNBC's 'Final Trades'
Johnson & Johnson Announces TREMFYA Is The First And Only IL-23 Inhibitor To Reduce Both The Signs And Symptoms And The Progression Of Structural Damage In Adults Living With Active Psoriatic Arthritis
New Study Shows Shingles Vaccine Linked To 20% Lower Dementia Risk, GSK Stock Pops